Welcome to our dedicated page for Longeveron SEC filings (Ticker: LGVN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Longeveron Inc. filings document a clinical-stage biotechnology issuer developing laromestrocel, an investigational allogeneic cellular therapy, and its related regulatory, financing, governance, and listing disclosures. Form 8-K reports cover FDA communications, clinical-development updates, material agreements, executive and board compensation matters, shareholder meeting actions, and Nasdaq continued-listing notices.
Registration statements and event reports also identify LGVN’s Class A common stock, Nasdaq Capital Market listing, emerging growth company status, and financing-related securities disclosures. The filing record ties the company’s public-company reporting to clinical and regulatory development of laromestrocel, stockholder voting matters, and capital resources used to fund biotechnology operations.
Longeveron Inc. appointed industry veteran Stephen H. Willard as permanent Chief Executive Officer, effective February 11, 2026, succeeding interim CEO Than Powell, who will remain in a business development role. Willard brings more than 30 years of pharma and biotech leadership experience, including multiple prior CEO positions.
Under a new letter agreement, Willard’s base salary is set at $500,000 per year, but roughly 50% will be temporarily deferred, alongside a similar deferral by Executive Chairman Dr. Joshua Hare, to support the company’s financial needs. During this deferral period, Willard will receive $250,000 per year, payable in cash or equity at the company’s discretion.
Willard is also slated to receive an initial equity package consisting of 200,000 shares of Class A common stock, 200,000 RSUs, and stock options for 200,000 shares, with equity vesting quarterly over four years. Separately, as part of broader cost-cutting tied to cash runway review, Longeveron is implementing a temporary 50% compensation reduction for its CEO and Executive Chairman, employee furloughs, reduced board fees, and travel limits, and plans to grant each affected executive 50,000 RSUs vesting around June 1, 2026.
Lincoln Alternative Strategies LLC reports that it no longer beneficially owns any shares of Longeveron Inc. common stock. The filing shows 0 shares beneficially owned, representing 0% of the class, with no sole or shared voting or dispositive power.
The filer confirms it owns 5 percent or less of Longeveron’s common stock and states that the securities referenced were not acquired or held for the purpose of changing or influencing control of the company.
Longeveron Inc. Chief Medical Officer Nataliya Agafonova reported a Form 4 transaction involving company Class A common stock. On 01/02/2026, 10,250 shares were withheld at a price of $0.593 per share, identified with transaction code "F," which the footnotes explain were shares withheld to satisfy tax obligations arising from the vesting of a restricted stock unit (RSU) award. Following this tax withholding, she beneficially owned 216,564 shares in total, which the disclosure notes includes RSUs that are still subject to future vesting.
Longeveron Inc. officer reports routine tax withholding transaction. General Counsel and Secretary Paul T. Lehr filed a Form 4 for a transaction on 01/02/2026 involving Class A Common Stock of Longeveron Inc. (LGVN).
The filing shows that 6,952 shares were withheld at a price of $0.593 per share to satisfy tax obligations tied to the vesting of a restricted stock unit (RSU) award. Following this tax withholding, Lehr beneficially owned 344,177 shares, which include RSUs that are subject to future vesting. This reflects an administrative equity compensation event rather than an open-market purchase or sale.
Longeveron Inc. Chief Financial Officer Lisa Locklear reported an insider transaction involving Class A Common Stock. On 01/02/2026, 10,250 shares were withheld at $0.593 per share to satisfy tax obligations in connection with the vesting of a restricted stock unit (RSU) award, rather than an open-market sale. Following this tax withholding, she beneficially owned 228,831 shares, which include RSUs subject to future vesting.
Longeveron Inc. Chief Executive Officer James Nathaniel Powell reported a routine tax-related transaction in the company’s Class A common stock. On 01/02/2026, 2,464 shares were withheld at a price of $0.593 per share to satisfy tax obligations arising from the vesting of a restricted stock unit (RSU) award.
After this withholding, Powell beneficially owned 125,593 shares of Longeveron Class A common stock on a direct basis, which includes RSUs that remain subject to future vesting.
Longeveron Inc. (LGVN) reported that two directors, Khoso Baluch and Neha Motwani, resigned from the Board of Directors, effective immediately on November 7, 2025.
The company stated the resignations were not due to any disagreement regarding its operations, policies, practices, management, or Board. The report was signed by Interim CEO Than Powell.
Longeveron Inc. furnished an 8‑K announcing it issued a press release with financial and operating results for the three and nine months ended September 30, 2025. The press release is attached as Exhibit 99.1. The Company states the information in Item 2.02 and Exhibit 99.1 is being furnished, not filed, under the Exchange Act.
Longeveron Inc. reported Q3 2025 results marked by much lower revenue and a wider loss as the company advances its lead cell therapy program. Total revenue was $137k for the quarter, down from $773k a year ago, reflecting a sharp decline in contract manufacturing activity. Net loss was $7.221M versus $4.419M in Q3 2024.
Cash and cash equivalents were $9.244M as of September 30, 2025. Management states this should fund operations late into Q1 2026 based on the current plan, and it has an ATM facility up to $10.7M in aggregate market value. The filing notes substantial doubt about the company’s ability to continue as a going concern without additional financing.
For the nine months ended September 30, 2025, revenue was $834k (vs. $1.789M in 2024) and net loss was $17.260M (vs. $11.892M). Operating expenses rose, with R&D at $9.321M and G&A at $9.113M. The company is prioritizing its HLHS program and anticipates a potential BLA filing in 2027 if the current ELPIS II trial is successful. As of October 31, 2025, shares outstanding were 19,848,876 Class A and 1,484,005 Class B.
Longeveron Inc. (LGVN) reported an insider equity award. A director acquired 34,000 shares of Class A common stock on 10/01/2025, recorded at a $0 price, as part of a time-based vesting RSU award.
Following the transaction, the reporting person beneficially owned 34,000 shares, held directly. The filing notes the holdings include RSUs subject to future vesting.